Office Address Home Address E-mail NeuroScience Consultants 8940 North Kendall Drive Suite 802-E Miami, Florida 33176 305-279-2979 749 Woodcrest Road Key Biscayne, Florida 33149 rafrv@bellsouth.net Date of Birth January 25, 1962 Place of Birth Miami, Florida Education 1983 Bachelor s of Science in Psychology Georgetown University 1990 Doctorate in Clinical Psychology Nova Southeastern University 2001 Master s of Science in Clinical Psychopharmacology Nova Southeastern University Pre-doctoral and Post-doctoral Training 1987 1990 Harvard Medical School/Massachusetts General Hospital 1992 1994 University of Miami School of Medicine Licensure 1991 Florida Board of Psychology, License #PY0004519 Board Certification 1997 American Board of Professional Psychology Diplomate in Clinical Psychology, Certificate #5039 Board Appointments 2002 Board of Psychology, Member Department of Health, State of Florida 2006 2007 Board of Psychology, Chairperson Department of Health, State of Florida 2010 Board of Psychology, Chairperson Department of Health, State of Florida
Page 2 Academic Appointments 1987 1990 Clinical Fellow in the Department of Psychiatry Harvard Medical School 1990 1992 Instructor in the Department of Psychiatry Harvard Medical School 1992 2001 Voluntary Assistant Professor in the Department of Neurology University of Miami Medical School 2003 Adjunct Associate Professor in the Department of Psychology University of Miami Staff Appointments 1987 1992 Clinical Fellow in Psychology Massachusetts General Hospital, Boston, MA 1989 1991 Staff Psychologist New England Memorial Hospital, Stoneham, MA 1992 1997 Consulting Staff Charter Hospital, Miami, FL 1992 Staff Psychologist Citrus Health Network, Hialeah, FL 1993 Active Staff Baptist Health Systems, Miami, FL Professional Experience 1989 1990 Coordinator of Inpatient Training for Pre-doctoral Internship Massachusetts General Hospital, Boston, MA 1990 1992 Staff Psychologist Massachusetts General Hospital, Boston, MA 1992 1994 Director, Mobile Crisis Services for Hurricane Andrew Relief Effort Northwest Dade Mental Health Center, Hialeah, FL 1994 Director, Assessment and Emergency Service Citrus Health Network, Hialeah, FL 1996 1998 Clinical Director AuroraCare Behavioral Managed Care Company, Miami, FL 1996 Neuropsychologist NeuroScience Consultants, Miami, FL 1998 Co-director and Investigator, Neuroscience Division Miami Research Associates, Miami, FL 1998 2001 Clinical Director Baptist Memory Disorders Center, Miami, FL
Page 3 Committee Assignments 1992 1994 South Florida Interprofessional Council Representative Dade County Psychological Association 1993 1994 Peer Review/Medical Records Committee Charter Hospital of Miami 1994 1995 Peer Review and Credentialing Committee Northwest Dade Mental Health Center 1995 2002 Psychopharmacology Committee, Chairperson Dade County Psychological Association 1995 Performance Improvement Committee Citrus Health Network 1997 2000 Quality Assurance/Utilization Management PsychStar Behavioral Managed Care Company 1997 2001 Medical Advisory Board Alzheimer s Association of Greater Miami 2000 2001 Quality Improvement Committee, Chairperson Citrus Health Network 2002 Psychology Steering Committee Baptist Health Systems 2002 2005 Continuing Education Committee Board of Psychology, State of Florida 2005 Probable Cause Panel, Chairperson Board of Psychology, State of Florida Memberships in Professional Associations 1986 Florida Psychological Association 1986 American Psychological Association 1993 International Neuropsychological Society 1995 Hispanic Neuropsychological Society Original Reports 1) Rivas-Vazquez, R., & Blais, M. (1997). Selective serotonin reuptake inhibitors and atypical antidepressants: A review and update for psychologists. Professional Psychology: Research and Practice, 28, 526 536. 2) Carrazana, E., DeToledo, J., Tatum, W., Wheeler, S., & Rivas-Vazquez, R. (1999). Epilepsy and religious experiences: Voodoo possession. Epilepsia, 40, 239 241. 3) Rivas-Vazquez, R., Johnson S.L., Blais, M., & Rey, G. (1999). Selective serotonin reuptake inhibitor discontinuation syndrome: Understanding, recognition and management for psychologists. Professional Psychology: Research and Practice, 30, 464 469. 4) Rey, G.J., Feldman, E., Rivas-Vazquez, R., Levin, B.E., & Benton, A.L. (1999). Neuropsychological test development and normative data on Hispanics. Archives of Clinical Neuropsychology, 14, 593 601.
Page 4 5) Rivas-Vazquez, R., Blais, M.A., Rey, G.J., & Rivas-Vazquez, A. (2000). Atypical antipsychotics: Pharmacologic profiles and psychologic implications. Professional Psychology: Research and Practice, 31, 628 640. 6) Rivas-Vazquez, R., Carrazana, E.J., Rey, G.J., Blais, M.A., & Racher, D.A. (2000). Alzheimer s disease: Pharmacologic treatment and management. The Clinical Neuropsychologist, 14, 93 109. 7) Rivas-Vazquez, R., Rivas-Vazquez A, Rey, G.J., & Blais, M.A. (2000). Sexual dysfunction associated with antidepressant treatment. Professional Psychology: Research and Practice, 31, 641 651. 8) Rivas-Vazquez, R., Carrazana, E.J., Rey, G.J., & Wheeler, S.D. (2000). Selective serotonin reuptake inhibitor discontinuation syndrome: Three cases presenting to a neurologic practice. The Neurologist, 6, 348 352. 9) Rivas-Vazquez, R. (2001). Antidepressants as first-line agents in the current pharmacotherapy of anxiety disorders. Professional Psychology: Research and Practice, 32, 101 104. 10) Carrazana, E., Rey, G., Rivas-Vazquez, R., & Tatum, W. (2001). Ictal alien hand syndrome. Epilepsy and Behavior, 2, 61 64. 11) Rivas-Vazquez, R., Blais, M., Rey, G., & Rivas-Vazquez, A. (2001). A brief reminder about documenting the psychological consultation. Professional Psychology: Research and Practice, 32, 194 199. 12) Rivas-Vazquez, R. (2001). Reboxetine: Refocusing on the role of norepinephrine in the treatment of depression. Professional Psychology: Research and Practice, 32, 211 214. 13) Rey, G.J., Feldman, E., Hernandez, D., Levin, B.E., Rivas-Vazquez, R., LeBlanc, W.G., & Benton, A.L. (2001). Application of the Multilingual Aphasia Examination - Spanish in the evaluation of Hispanic patients post-traumatic brain injury. The Clinical Neuropsychologist, 15, 13 18. 14) Rivas-Vazquez, R. (2001). St. John s wort (Hypericum perforatum): Practical considerations based on the evidence. Professional Psychology: Research and Practice, 32, 329 332. 15) Carrazana, E.J., Rivas-Vazquez, R., Rey J, & Rey, G.J. (2001). SSRI discontinuation syndrome exacerbated by buspirone (letter). American Journal of Psychiatry, 158, 966 967. 16) Rivas-Vazquez, R. (2001). Cholinesterase inhibitors: Current pharmacological treatments for Alzheimer's disease. Professional Psychology: Research and Practice, 32, 433 436. 17) Blais, M., Rivas-Vazquez, R., Rey, G.J., Racher, D.A., & Carrazana, E.J. (2001). Treatment and management of Alzheimer's disease. Clinical Geriatrics, 9, 58 65. 18) Rivas-Vazquez, R. (2001). Understanding drug interactions. Professional Psychology: Research and Practice, 32, 543 547. 19) Rivas-Vazquez, R., Rivas-Vazquez, A., Blais, M., Rey, G.J., Rivas-Vasquez, F., Jacobo, M., & Carrazana, E.J. (2001). Development of a Spanish version of the Schwartz Outcome Scale - 10: A brief mental health outcome measure. Journal of Personality Assessment, 77, 436 446.
Page 5 20) Rivas-Vazquez, R. (2001). Ziprasidone: Pharmacological and clinical profile of the newest atypical antipsychotic. Professional Psychology: Research and Practice, 32, 662 665. 21) Rivas-Vazquez, R., & Blais, M. (2002). Pharmacologic treatment of personality disorders. Professional Psychology: Research and Practice, 33, 101 104. 22) Rivas-Vazquez, R., Johnson, S.L., Rey, G.J., & Blais, M. (2002). Current treatments for bipolar disorder: A review and update for psychologists. Professional Psychology: Research and Practice, 33, 212 223. 23) Rivas-Vazquez, R., & Rey, J. (2002). Weight gain and metabolic disturbances associated with the atypical antipsychotics. Professional Psychology: Research and Practice, 33, 341 344. 24) Rivas-Vazquez, R., & Delgado, L. (2002). Clinical and toxic effects of MDMA ( Ecstasy ). Professional Psychology: Research and Practice, 33, 422 425. 25) Rivas-Vazquez, R., & Mendez, C.I. (2002). Overview of the drug approval process. Professional Psychology: Research and Practice, 33, 502 506. 26) Blais, M.A., Matthews, J., Lipkis-Orlando, R., O Keefe, S.M., Jacobo, M., Rivas- Vazquez, R.A, & Summergrad, P. (2002). Development and application of a multifaceted tool for evaluating inpatient psychiatric care. Administration and Policy in Mental Health, 30, 159 172. 27) Rivas-Vazquez, R.A. (2003). Aripiprazole: A novel antipsychotic with dopamine stabilizing properties. Professional Psychology: Research and Practice, 34, 108 111. 28) Rivas-Vazquez, R.A., & Perel, J.M. (2003). The role of stereochemistry and chiral pharmacology in psychotropic drug development. Professional Psychology: Research and Practice, 34, 210 213. 29) Rivas-Vazquez, R.A. (2003). Benzodiazepines in contemporary clinical practice. Professional Psychology: Research and Practice, 34, 324 328. 30) Feldman, L.B., & Rivas-Vazquez, R.A. (2003). Assessment and treatment of social anxiety disorder. Professional Psychology: Research and Practice, 34, 396 405. 31) Rivas-Vazquez, R.A, & Resnick, M. (2003). The emerging role of glutamate in the pathophysiology and treatment of psychiatric disorders. Professional Psychology: Research and Practice, 34, 444 448. 32) Rivas-Vazquez, R.A, Rice, J., & Kalman, D. (2003). Pharmacotherapy of obesity and eating disorders. Professional Psychology: Research and Practice, 34, 562 566. 33) Rivas-Vazquez, R.A. (2003). Atomoxetine: A selective norepinephrine reuptake inhibitor for the treatment of Attention-Deficit/Hyperactivity Disorder. Professional Psychology: Research and Practice, 34, 666 669. 34) Rivas-Vazquez, R.A, Mendez, C., Rey, G.J., & Carrazana, E.J. (2004). Mild cognitive impairment: New neuropsychological and pharmacological target. Archives of Clinical Neuropsychology, 19, 11 27. 35) Rivas-Vazquez, R.A, Saffa-Biller, D., Ruiz, I., Blais, M.A., & Rivas-Vazquez, A. (2004). Current issues in anxiety and depression: Comorbid, mixed and subthreshold disorders. Professional Psychology: Research and Practice, 35, 74 83.
Page 6 36) Rivas-Vazquez, R.A., Sarria, M., Rey, G., Rivas-Vazquez, A., Rodriguez, J. & Jardon, M. (2009). A relationship-based care model for jail diversion. Psychiatric Services, 60, 766 771. 37) Rivas-Vazquez, R.A., Bello, I., Sarria, M., Fernandez, N., & Rey, G.J. (2011). Prevalence of Metabolic Syndrome in a Predominantly Cuban, Psychiatrically Ill and Homeless Population. Primary Care Companion for CNS Disorders, 13(3), e1 e5. 38) Rey, G.J., Rivas-Vazquez, R., Garaycoa, G., Mendez, C., Bello, I., & Carrazana, E.J. (in press). A prospective study monitoring AD patients during a switch from donepezil to rivastigmine. The Neurologist. 39) Blais, M.A., Blagys, M.D., Lechner, E., Rivas-Vazquez, R., Martinez-Arrue, R., Orlandini, E., & Bello, I. (in press). Development and initial validation of an ultrabrief measure of psychiatric symptom distress. Journal of Personality Assessment. 40) Rey, G.J., Schatz, N., Bauerlain, E.J., Bowen, B., Rivas-Vazquez, R., & Carrazana, E.J. (under review). Transient Balint's syndrome following heart transplantation. Neuroophthalmology. Book Chapters 1) Blais, M., Smallwood, P., Groves, J., & Rivas-Vazquez R. Personality and Personality Disorders. In T. Sterns, J. Rosenbaum, M. Fava, J. Biedermen & S. Rauch (Ed.) Handbook of Comprehensive Clinical Psychiatry (2008, pp. 527-542). Abstracts 1) Rivas-Vazquez, A., & Rivas-Vazquez, R. (1986, May). Family restructuring: An alternative to teen suicide. Presented at the American Association of Suicidology Conference, Atlanta, Georgia. 2) Rey, G.J., Feldman, E., Rivas-Vazquez, R., & Benton, A.L. (1994, August). Current trends and future of neuropsychological research with Hispanics. Presented at the annual meeting of the American Psychological Association, Los Angeles, California. 3) Rey, G.J., Levin, B.E., Brown, M.C., Feldman, E., Rivas-Vazquez, R., Arias, M., & Benton, A.L. (1995). Application of the Benton tests to Hispanic adults: A preliminary analysis. Journal of the International Neuropsychological Society, 1. 4) Carrazana, E., DeToledo, J., Tatum, W., Rivas-Vazquez, R., Rey, G., Wheeler, S., & Ramirez-Mejia, C. (1998, December). Epilepsy and religious experiences: Voodoo possession. Presented at the annual meeting of the American Epilepsy Society, San Diego, California. 5) Carrazana, E., DeToledo, J., Tatum, W., Rivas-Vazquez, R., Rey, G., Wheeler, S., & Ramirez-Mejia, C. (1998, December). Erroneous attribution of epileptic seizures to voodoo spirit possession. Presented at the troisieme Congres de Neurologie Tropicale, Martinique. 6) Rivas-Vazquez, R., Carrazana, E.J., Rey, G.J., & Mendoza, R. (1999, January). Clinical and psychosocial characteristics of Caribbean and Anglo-Saxon dementia referrals in South Florida. Presented at the tenth annual meeting of the American Neuropsychiatric Association, New Orleans, Louisiana.
Page 7 7) Rey, G.J., Rivas-Vazquez, R., Feldman, E., & Carrazana, E.J. (1999, January). The evaluation of executive functions in Hispanics. Presented at the tenth annual meeting of the American Neuropsychiatric Association, New Orleans, Louisiana. 8) Carrazana, E.J., Wheeler, S., Aptman, M., Zwibel, H., Kobetz, S., Racher, D., Grant, T., Faradji, V., Ramirez-Mejia, C., Rivas-Vazquez, R., & Rey, G.J. (1999, December). Second generation anticonvulsants utilization in clinical neurology (abstract #10022). Presented at the annual meeting of the American Epilepsy Society, Orlando, Florida. 9) Rivas-Vazquez, R., Rey, G.J., Blais, M.A., Carrazana, E.J., & Schwartz, H. (2000, June). Development and validation of the Spanish version of the Schwartz Outcome Scale - 10. Presented at the 40 th annual New Clinical Drug Evaluation Unit meeting, Boca Raton, Florida. 10) Rey, G.J., Rivas-Vazquez, R., Carrazana, E.J., Mendoza, R., Garaycoa, G., & Schwartz, H. (2000, June). Cross-cultural comparisons of dementia referrals in South Florida: Clinical and psychosocial factors. Presented at the 40th annual New Clinical Drug Evaluation Unit meeting, Boca Raton, Florida. 11) Carrazana, E.J., Espinosa, I., Wheeler, S., Espinosa, J., Rey, G.J., Rivas-Vazquez, R., & Ramirez-Mejia, C. (2000, December). Is folic acid for reduction of anticonvulsants teratogenic risk part of the standard neuropsychiatric clinical practice? Results of a survey. Presented at the annual meeting of the American Epilepsy Society, Los Angeles, California. 12) Rey, G.J., Carrazana, E.J., Garaycoa, G., Rivas-Vazquez, R., Espinosa, I., & Ramirez- Mejia, C. (2000, December). Affective disorders in juvenile myoclonic epilepsy: A prospective study. Presented at the annual meeting of the American Epilepsy Society, Los Angeles, California. 13) Johnson, S.L., Rugerro, C., Winters, R., Gotlib, I.H., Ahmed, Z., & Rivas-Vazquez, R. (2001, July). The behavioral activation system and mania: Cognitive-behavioral implications. Presented at the annual meeting of the World Congress of Behavioral and Cognitive Therapies, Vancouver, British Columbia. 14) Blagys, M.D., Blais, M.A., Lechner, E., Rivas-Vazquez, R., Martinez-Arrue, R., Orlandini, E., & Bello, I. (2002, March). Initial development of an ultra-brief measure of psychiatric symptoms distress: The AT-25. Presented at the midwinter meeting of the Society for Personality Assessment meeting, San Antonio, Texas 15) Miller, D., Gonzalez, E., Rivas-Vazquez, R., & Blais, M.A. (2002, March). The Word Association Test (WAT): A predictor of suicide? Presented at the midwinter meeting of the Society for Personality Assessment meeting, San Antonio, Texas 16) Rey, G.J., Garaycoa, G., Rivas-Vazquez, R., Bello, I., Campos, L., & Carrazana, E.J. (2002, May). Clinical and neuropsychological findings in patients with Alzheimer s disease during switch from donepezil to rivastigmine. Presented at the annual meeting of the American Geriatrics Society, Washington, D.C. 17) Rey, G.J., Rivas-Vazquez, R., Mendoza, R., Garaycoa, G., & Carrazana, E. (2005, February). A Spanish verbal learning test: normative and clinical data. Presented at the 33 rd annual International Neuropsychological Society meeting, San Louis, Missouri.
Page 8 18) Rey, G.J., Mendez, C., Rivas-Vazquez, R., & Bello, I. (2005, February). Neuropsychiatric symptomatology and caregiver distress in Alzheimer s Disease: A comparison of Hispanic and Anglosaxon groups. Presented at the 33 rd annual International Neuropsychological Society meeting, San Louis, Missouri. 19) Sarria, M., Rivas-Vazquez, R.A., & Martinez, H. (2008, March). Relationship-based care effects on jail diversion. Presented at the 2008 CMHS National GAINS Center Conference, Washington, D.C. Other Publications 1) Rivas-Vazquez, R. (1990). Assessing differential levels of affective expression in bilingual subjects using the Thematic Apperception Test. Unpublished doctoral dissertation. Nova Southeastern University, Florida. 2) Rivas-Vazquez, R., & Samek, W.R. (1996). Update on prescription privileges. Florida Psychologist, 47, 26 27. 3) Carrazana, E.J., & Rivas-Vazquez, R. (1999). Antiepileptic drugs in the management of mood disorders. Monograph supported by unrestricted grant from Parke- Davis/Warner Lambert. 4) Rivas-Vazquez, R., Johnson, S.L., Blais, M., & Rey, G. (2000). Recognizing SSRI discontinuation syndrome. Clinician s Research Digest, 18, 3. Lectures and Presentations 1) Effects of language on assessment and treatment of Hispanic patients. Presented at Massachusetts General Hospital/Chelsea Mental Health Center Teaching Rounds, May 1991, Boston, Massachusetts. 2) Introduction to DSM-IV. Presented at Northwest Dade Mental Health Center Grand Rounds, August 1994, Hialeah, Florida. 3) Clinical best practices in Medicaid managed care. Presented at Public/Private Regional Symposia: Integrating Public and Private Funding Streams and Delivery Systems in Behavioral Health Care, October 1996, Clearwater Beach, Florida. 4) An update on Medicaid managed care in Florida. Presented at Linking Forces VI: The Sixth Annual Children's Mental Health Conference, May 1997, Miami, Florida. 5) Overview of Alzheimer's disease. Presented at The Alzheimer's Association Fifth Annual Educational Forum, November 1997, Miami, Florida. 6) Alzheimer's management and treatment issues. Sponsored by the Puerto Rican Neurophysiology Society and Pfizer-Eisai Pharmaceutical Companies. May 1998, San Juan, Puerto Rico. 7) Dementia 99: An update in diagnosis, treatment and reimbursement. Sponsored by Novartis Pharmaceuticals Corporation. February 1999, Boca Raton, Florida. 8) Psychological aspects of headaches. Presented at the Baptist Hospital Symposium for migraine management May 1999, Miami, Florida. 9) Impact of psychosocial stress on diabetes control. Presented at the Diabetes 2000: Management strategies for the new millennium. Sponsored by the Diabetes Care Centers of Baptist Health Systems. July 1999, Barcelona, Spain.
Page 9 10) Cognitive issues associated with the use of antipsychotics in elderly patients. Presented at the Novartis Advisory Board Meeting: Psychosis in the elderly patient. February 2002, New Orleans, Louisiana. 11) Baker act: Responsibilities and risks under the law. Presented at the South Florida Hospital and Healthcare Association Meeting, November 2008, Weston, Florida. Pharmaceutical Associations 1998 2000 Parke-Davis, Warner Lambert Pharmaceutical Speakers Bureau 1998 2001 Janssen Pharmaceutica Speakers Bureau 1999 2002 Novartis Pharmaceuticals Corporation National Speakers Bureau 1999 2002 Eisai Inc., Speakers Bureau Research Experience 1) Principal Investigator, Berlex Laboratories: Multiple Sclerosis, June 1995 2) Sub-investigator, Parke-Davis: Alzheimer s Disease, April 1996 3) Sub-investigator, Protodigm, LTD: Alzheimer's Disease, May 1997 4) Sub-investigator, Bristol Myers Squibb: Generalized Anxiety Disorder, June 1997 5) Sub-investigator, Bayer Pharmaceuticals: Alzheimer's Disease, September 1997 6) Sub-investigator, Takeda: Alzheimer's Disease, March 1998 7) Sub-investigator, Bristol-Myers Squibb: Generalized Anxiety Disorder, April 1998 8) Sub-investigator, Merck & Co., Inc.: Major Depressive Disorder, April 1998 9) Principal Investigator, SmithKline Beecham: Generalized Anxiety Disorder, December 1998 10) Principal Investigator, SmithKline Beecham: Posttraumatic Stress Disorder, February 1999 11) Sub-investigator, Eisai: Dementia Associated with Cerebrovascular Disease, February 1999 12) Sub-investigator, Medeva Development: Pediatric Attention Deficit Hyperactivity Disorder, April 1999 13) Sub-investigator, Bristol-Myers Squibb: Pediatric Generalized Anxiety Disorder, July 1999 14) Sub-investigator, Bristol-Myers Squibb: Major Depressive Disorder, July 1999 15) Sub-investigator, Neo-Therapeutics: Alzheimer's Disease, September 1999 16) Sub-investigator, SmithKline Beecham: Premenstrual Dysphoric Disorder, September 1999 17) Sub-investigator, Eisai: Dementia Associated with Cerebrovascular Disease, October 1999 18) Sub-investigator, Novartis: Mild Cognitive Impairment, December 1999 19) Sub-investigator, Tap Holdings, Inc.: Major Depressive Disorder, January 2000 20) Principal Investigator, Wyeth-Ayerst: Social Anxiety Disorder, February 2000 21) Sub-investigator, Eli Lilly: Pediatric Attention Deficit Hyperactivity Disorder, March 2000 22) Sub-investigator, Pharmacia-Upjohn: Major Depressive Disorder, April 2000 23) Sub-investigator, Eli Lilly: Generalized Anxiety Disorder, August 2000
Page 10 24) Sub-investigator, Wyeth-Ayerst: Pediatric Generalized Anxiety Disorder, August 2000 25) Sub-investigator, Wyeth-Ayerst: Adolescent Social Anxiety Disorder, August 2000 26) Sub-investigator, Pharmacia-Upjohn: Major Depressive Disorder, October 2000 27) Sub-investigator, Pfizer: Alzheimer's Disease, February 2001 28) Sub-investigator, Forest Laboratories: Generalized Anxiety Disorder, March 2001 29) Sub-investigator, Janssen: Alzheimer's Disease, March 2001 30) Sub-investigator, Forest Laboratories: Moderate to Severe Alzheimer's Disease, April 2001 31) Sub-investigator, SmithKline Beecham: Major Depressive Disorder with Anxiety, April 2001 32) Sub-investigator, Janssen: Mild Cognitive Impairment, April 2001 33) Sub-investigator, Wyeth-Ayerst: Panic Disorder, April 2001 34) Sub-investigator, Forest Laboratories: Generalized Anxiety Disorder, May 2001 35) Sub-investigator, Eli Lilly: Schizophrenia, September 2001 36) Sub-investigator, Eli Lilly: Pediatric Attention Deficit Hyperactivity Disorder, September 2001 37) Sub-investigator, GlaxoSmithKline: Major Depressive Disorder, September 2001 38) Sub-investigator, Pfizer: Major Depressive Disorder with Somatic Symptoms, September 2001 39) Sub-investigator, Shire Laboratories: Pediatric Attention Deficit Hyperactivity Disorder, September 2001 40) Sub-investigator, Shire Laboratories: Adult Attention Deficit Hyperactivity Disorder, December 2001 41) Sub-investigator, Novartis: Cerebrovascular Dementia, February 2002 42) Sub-investigator, Eli Lilly: Antipsychotic-induced weight gain, March 2002 43) Sub-investigator, Forest Laboratories: Mild to Moderate Alzheimer's Disease, April 2002 44) Sub-investigator, Pharmacia Upjohn: Generalized Anxiety Disorder, April 2002 45) Sub-investigator, Eli Lilly: Pediatric Attention Deficit Hyperactivity Disorder, July 2002 46) Principal Investigator, Wyeth-Ayerst: Major Depressive Disorder, October 2002 47) Sub-investigator, Eli Lilly: Fibromyalgia with or without depression, November 2002 48) Sub-investigator, Forest Laboratories: Major Depressive Disorder, November 2002 49) Sub-investigator, Sanofi-Synthelabo: Smoking Cessation, November 2002 50) Sub-investigator, Shire Laboratories: Pediatric Attention Deficit Hyperactivity Disorder, December 2002 51) Sub-investigator, Johnson & Johnson: Mild Cognitive Impairment, January 2003 52) Sub-investigator, GlaxoSmithKline: Major Depressive Disorder, April 2003 53) Sub-investigator, Sanofi-Synthelabo: Alzheimer's Disease, June 2003 54) Sub-investigator, Sanofi-Synthelabo: Major Depressive Disorder, August 2003 55) Sub-investigator, Boehringer-Ingelheim: Parkinson's Disease, September 2003 56) Sub-investigator, Pfizer: Fibromyalgia, October 2003 57) Sub-investigator, Eli Lilly: Pediatric Attention Deficit Hyperactivity Disorder, November 2003
Page 11 58) Sub-investigator, Merck & Co., Inc.: Alzheimer's Disease, November 2003 59) Sub-investigator, Wyeth Research: Alzheimer's Disease, November 2003 60) Principal Investigator, Wyeth Research: Major Depressive Disorder, December 2003 61) Sub-investigator, Cephalon: Pediatric Attention Deficit Hyperactivity Disorder, January 2004 62) Sub-investigator, Eli Lilly: Pediatric Attention Deficit Hyperactivity Disorder and Dyslexia, January 2004 63) Principal Investigator, Wyeth Research: Major Depressive Disorder, January 2004 64) Sub-investigator, Sepracor: Insomnia related to Major Depressive Disorder, March 2004 65) Sub-investigator, Cephalon: Pediatric Attention Deficit Hyperactivity Disorder, May 2004 66) Sub-investigator, GlaxoSmithKline: Parkinson's Disease, May 2004 67) Sub-investigator, Schering-Plough: Hepatitis C, May 2004 68) Sub-investigator, Sanofi-Synthelabo: Fibromyalgia, June 2004 69) Sub-investigator, Shire Laboratories: Adult Attention Deficit Hyperactivity Disorder, September 2004 70) Sub-investigator, Shire Laboratories: Adolescent Attention Deficit Hyperactivity Disorder, September 2004 71) Sub-investigator, Shire Laboratories: Pediatric Attention Deficit Hyperactivity Disorder, September 2004 72) Sub-investigator, Eli Lilly: Major Depressive Disorder, November 2004 73) Sub-investigator, Cephalon: Generalized Anxiety Disorder, November 2004 74) Sub-investigator, Pfizer: Insomnia, November 2004 75) Sub-investigator, Cephalon: Generalized Anxiety Disorder, January 2005 76) Sub-investigator, Novartis: Generalized Anxiety Disorder, March 2005 77) Sub-investigator, Sanofi-Synthelabo: Major Depressive Disorder, March 2005 78) Sub-investigator, Shire Laboratories: Adult Attention Deficit Hyperactivity Disorder, March 2005 79) Sub-investigator, Cephalon: Narcolepsy in Children and Adolescents, June 2005 80) Sub-investigator, Cephalon: Obstructive Sleep Apnea in Children and Adolescents, June 2005 81) Sub-investigator, Eli Lilly: Fibromyalgia, July 2005 82) Sub-investigator, Cephalon: Excessive Sleepiness in Children and Adolescents, July 2005 83) Sub-investigator, Shire Laboratories: Pediatric Attention Deficit Hyperactivity Disorder, July 2005 84) Sub-investigator, Shire Laboratories: Adult Attention Deficit Hyperactivity Disorder, July 2005 85) Sub-investigator, Sanofi-Synthelabo: Generalized Anxiety Disorder, December 2005 86) Sub-investigator, Pfizer/Neurocrine Biosciences: Insomnia and Major Depressive Disorder, November 2005 87) Sub-investigator, Pfizer: Generalized Anxiety Disorder, November 2005 88) Principal Investigator, Wyeth Research: Major Depressive Disorder, February, 2006
Page 12 89) Sub-investigator, Wyeth Research: Fibromyalgia, June 2006 90) Sub-investigator, New River Pharmaceuticals: Adult Attention Deficit Hyperactivity Disorder, June 2006 91) Sub-investigator, Wyeth Research: Fibromyalgia (Open-label Extension), August 2006 92) Sub-investigator, New River Pharmaceuticals: Adult Attention Deficit Hyperactivity Disorder, September 2006 93) Sub-investigator, INC Research: Mild Cognitive Impairment following Coronary Artery Bypass Graft, October 2006 94) Sub-investigator, Novartis: Major Depressive Disorder, October 2006 95) Sub-investigator, Eisai: Parkinson's Disease, November 2006 96) Sub-investigator, Wyeth Research: Alzheimer's Disease, November 2006 97) Sub-investigator, Boehringer-Ingelheim: Parkinson's Disease, December 2006 98) Sub-investigator, Shire Development Inc: Pediatric Attention Deficit Hyperactivity Disorder with Oppositionality, January 2007 99) Sub-investigator, Eli Lilly: Adult Attention Deficit Hyperactivity Disorder, January 2007 100) Sub-investigator, Shire Pharmaceutical Development Inc: Pediatric Attention Deficit Hyperactivity Disorder, January 2007 101) Sub-investigator, Eli Lilly: Chronic Lower Back Pain, January 2007 102) Principal Investigator, Wyeth Research: Major Depressive Disorder, March 2007 103) Sub-investigator, Shire Laboratories: Pediatric Attention Deficit Hyperactivity Disorder, May2007 104) Sub-investigator, Shire Laboratories: Adolescent Attention Deficit Hyperactivity Disorder, May 2007 105) Sub-investigator, Eli Lilly: Pediatric Major Depressive Disorder, June 2007 106) Sub-investigator, Wyeth Research: Alzheimer's Disease, June 2007 107) Sub-investigator, Shire Laboratories: Adolescent Attention Deficit Hyperactivity Disorder, July 2007 108) Sub-investigator, Abbott Laboratories: Adult Attention Deficit Hyperactivity Disorder, July 2007 109) Sub-investigator, Pfizer Inc: Generalized Anxiety Disorder, August 2007 110) Sub-investigator, Arena Pharmaceuticals, Obesity, January 2008 111) Sub-investigator, Novartis, Major Depressive Disorder, February 2008 112) Sub-investigator, Johnson and Johnson PRD, LLC: Adult Attention Deficit Hyperactivity Disorder, March 2008 113) Sub-investigator, Elan: Alzheimer's Disease, April 2008 114) Sub-investigator, Takeda: Major Depressive Disorder, April 2008 115) Sub-investigator, Pfizer Inc: Adults with Nonrestorative Sleep, April 2008 116) Sub-investigator, Sepracor: Pediatric Attention Deficit Hyperactivity Disorder with Insomnia, June 2008 117) Sub-investigator, Eli Lilly, Fibromyalgia, June 2008 118) Sub-investigator, Takeda: Generalized Anxiety Disorder, June 2008 119) Sub-investigator, Pfizer Inc: Generalized Anxiety Disorder, June 2008 120) Sub-investigator, Schering-Plough: Obesity, July 2008
Page 13 121) Sub-investigator, Shire Laboratories, Adolescent Attention Deficit Hyperactivity Disorder, September 2008 122) Sub-investigator, Novartis, Pediatric Attention Deficit Hyperactivity Disorder, October 2008 123) Sub-investigator, Shire Laboratories, Pediatric Attention Deficit Hyperactivity Disorder (Extension), November 2008 124) Sub-investigator, Pfizer Inc., Generalized Anxiety Disorder (Open-label Extension), November 2008 125) Sub-investigator, Pfizer Inc., Alzheimer's Disease, December 2008 126) Sub-investigator, Bristol-Myers Squibb, Alzheimer's Disease, December 2008 127) Sub-investigator, Johnson and Johnson PRD, LLC, Adult Attention Deficit Hyperactivity Disorder, March 2009 128) Sub-investigator, Eli Lilly, Osteoarthritis Knee Pain, March 2009 129) Sub-investigator, Neurogen Corporation, Restless Leg Syndrome, April 2009 130) Sub-investigator, Mylan Pharmaceuticals, Inc, Schizophrenia, June 2009 131) Principle Investigator, Wyeth Research, Major Depressive Disorder, June 2009 132) Sub-investigator, Shire Laboratories, Adult Attention Deficit Hyperactivity Disorder, June 2009 133) Sub-investigator, Eli Lilly, Pediatric Attention Deficit Hyperactivity Disorder, July 2009 134) Principle Investigator, Wyeth Research, Major Depressive Disorder, July 2009 135) Sub-investigator, Pfizer Inc., Sleep Maintenance, July 2009 136) Sub-investigator, Eli Lilly, Pediatric Attention Deficit Hyperactivity Disorder (Openlabel Extension), September 2009 137) Sub-investigator, Cephalon, Mild to Moderate Closed Traumatic Brain Injury, October 2009 138) Sub-investigator, Eli Lilly, Obesity, October 2009 139) Sub-investigator, Bristol-Myers Squibb, Alzheimer's Disease, October 2009 140) Sub-investigator, Elan, Alzheimer's Disease (Extension), December 2009 141) Sub-investigator, Pfizer, Restless Legs Syndrome, January 2010 142) Sub-investigator, Tibotec Pharmaceuticals, Hepatitis C, January 2010 143) Sub-investigator, Cephalon, Excessive Sleepiness Associated with Shift Work, March 2010 144) Sub-investigator, Forest Laboratories, Major Depressive Disorder, March 2010 145) Sub-investigator, Otsuka, Adult Attention Deficit Hyperactivity Disorder, June 2010 146) Sub-investigator, Novartis, Major Depressive Disorder, July 2010 147) Sub-investigator, Novartis, Migraines, November 2010 148) Sub-investigator, Novartis, Pediatric Attention Deficit Hyperactivity Disorder, December 2010 149) Sub-investigator, Janssen, Alzheimer's Disease, January 2011 150) Sub-investigator, Eli Lilly, Migraines, March 2011 151) Sub-investigator, AstraZeneca, Major Depressive Disorder, May 2011 152) Sub-investigator, Abbott, Major Depressive Disorder, June 2011
Page 14 153) Sub-investigator, Shire Laboratories, Adolescent Attention Deficit Hyperactivity Disorder, October 2011 154) Sub-investigator, Shionogi Inc., Pediatric Attention Deficit Hyperactivity Disorder, October 2011 155) Sub-investigator, Roche, Multiple Sclerosis, November 2011 156) Sub-investigator, Bristol-Myers Squibb, Migraines, November 2011 157) Sub-investigator, Pfizer, Sensorineural Hearing Loss, December 2011 158) Sub-investigator, Forest Laboratories, Major Depressive Disorder, December 2011 UPDATED DECEMBER 2011